Medy-Tox Inc. (KOSDAQ:086900)
119,800
+300 (0.25%)
Aug 29, 2025, 9:39 AM KST
Medy-Tox Revenue
Medy-Tox had revenue of 61.65B KRW in the quarter ending June 30, 2025, a decrease of -5.17%. This brings the company's revenue in the last twelve months to 234.63B, down -4.72% year-over-year. In the year 2024, Medy-Tox had annual revenue of 228.62B with 3.39% growth.
Revenue (ttm)
234.63B
Revenue Growth
-4.72%
P/S Ratio
3.58
Revenue / Employee
332.81M
Employees
724
Market Cap
838.82B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 228.62B | 7.50B | 3.39% |
Dec 31, 2023 | 221.12B | 26.02B | 13.34% |
Dec 31, 2022 | 195.10B | 10.23B | 5.53% |
Dec 31, 2021 | 184.87B | 44.04B | 31.27% |
Dec 31, 2020 | 140.83B | -65.07B | -31.60% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
PharmaResearch | 392.31B |
Peptron | 4.30B |
LigaChem Biosciences | 146.42B |